Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Management of Insomnia

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

Sedatives and Hypnotics: Overview

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...

Cholinergic Antagonists: Pharmacokinetics

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Presentation and temporal nature of postacute sequelae of SARS-CoV-2 infection in a US national cohort.

Brain, behavior, & immunity - health·2026

Same author

Toward precision medicine in delayed sleep-wake phase disorder: Definitions, dimensions, and the path to personalised care.

Sleep medicine reviews·2026

Same author

The predictive role of daily emotional dynamics in depression, anxiety, and academic performance: A longitudinal study in adolescents.

Journal of affective disorders·2026

Same author

Current sleep interventions for shift workers: a mini review to shape a new preventative, multicomponent sleep management programme.

Frontiers in sleep·2025

Same author

Factors associated with seeking and receiving home antiviral therapy during the coronavirus disease 2019 (COVID-19) pandemic.

Discover public health·2025

Same author

Association of Prior COVID-19 Infection with Restorative Sleep Quality Using REST-Q Scores: Findings from the COPE Initiative.

medRxiv : the preprint server for health sciences·2025

Search research articles

Related Experiment Video

Updated: Jun 29, 2026

Polygraphic Recording Procedure for Measuring Sleep in Mice

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Melatonin and its agonists: an update.

Josephine Arendt, Shantha M W Rajaratnam

The British Journal of Psychiatry : the Journal of Mental Science

|October 2, 2008

Summary

Melatonin, a pineal hormone, regulates circadian rhythms and sleep. Agomelatine, a melatonin agonist and serotonin antagonist, shows therapeutic potential for sleep disorders and depression.

Area of Science:

Neuroscience
Chronobiology
Pharmacology

Background:

The pineal hormone melatonin influences circadian rhythms, notably the sleep-wake cycle.
Melatonin agonists possess therapeutic potential for circadian rhythm sleep disorders.

Discussion:

Agomelatine, a specific agent, targets depression.
Agomelatine acts as a serotonin-2C (5-HT2C) antagonist.

Key Insights:

Melatonin's role in circadian rhythm regulation is established.
Agomelatine combines melatonin agonism with 5-HT2C antagonism for dual therapeutic action.

Outlook:

Further research into agomelatine's efficacy for sleep disorders and depression is warranted.
Investigating the synergistic effects of melatonin agonism and 5-HT2C antagonism could yield novel therapeutic strategies.

More Related Videos

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

Related Experiment Videos

Last Updated: Jun 29, 2026

Polygraphic Recording Procedure for Measuring Sleep in Mice

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019